增长激素的使用改善了超重/肥胖患者的非酒精性脂肪性肝病:一项随机试验
Laura E Dichtel1, Kathleen E Corey2, Melanie S Haines1
1Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital/Harvard Medical School, Boston, MA 02114, USA.
The Journal of clinical endocrinology and metabolism
|June 28, 2023
概括
在肥胖和非酒精性脂肪性肝病 (NAFLD) 的成年人中,生长激素 (GH) 治疗减少了肝脂肪. 这项研究表明,GH可能是NAFLD的未来治疗方法,而不会对血糖水平产生负面影响.
科学领域:
- 内分泌学 在内分泌学.
- 肝病学 肝病学是一种肝病学.
- 代谢疾病 代谢疾病
背景情况:
- 超重和肥胖与生长激素 (GH) 缺乏有关,有助于非酒精性脂肪肝疾病 (NAFLD).
- NAFLD是一种进展性肝脏疾病,治疗选择有限.
研究的目的:
- 调查GH在减轻超重/肥胖和NAFLD患者肝硬化症中的疗效.
主要方法:
- 一项为期6个月的随机,双盲,安慰剂对照试验,涉及53名BMI≥25 kg/m2和NAFLD (没有糖尿病) 的成年人.
- 参与者每天接受皮下GH或安慰剂,目标是将胰岛素样生长因子1 (IGF-1) 向正常四分位数的上方.
- 在治疗前和治疗后使用质子磁共振光谱 (1H-MRS) 测量肝脏内脂含量 (IHL).
主要成果:
- 与安慰剂相比,GH的使用导致IHL显著减少 (-8.9%的净治疗效果).
- 两组之间的副作用是可比的,在GH组中发现的轻度胀更多.
- 没有观察到对血糖指标或胰岛素耐药性的显著不良影响.
结论:
- GH疗法有效地降低了NAFLD超重/肥胖成年人的肝硬化症.
- GH/IGF-1轴为管理NAFLD提供了潜在的治疗点.
相关概念视频
Hypoglycemia and Glucagon
306
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
306
Insulin: Dosing Regimen and Adverse Effects
214
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
214
Glucagon-like Receptor Agonists
366
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
366
Hormones Regulating Blood Glucose
3.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.6K
Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
Obesity
549
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
549


